CardioExchange Archive

October 28th, 2013

Selections from Richard Lehman’s Literature Review: October 28th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include thrombus aspiration during STEMI, the effect of statins on mortality in patients with ventilator-associated pneumonia, and more.

---

August 21st, 2012

Shining a Light on Standards at Medical Journals

Druin Burch, BM BCh MA MSc, John Stephen Yudkin, MB BChir MD FRCP and Marion Marjorie Mafham, MBChB MD

Recent articles in the diabetes literature might provide more evidence about editorial standards than about glycemic control.

---

August 8th, 2012

Selections from Richard Lehman’s Literature Review: August 8th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include heart failure and depression, endoscopic vs. open vein-graft harvest for CABG, linagliptin vs. glimepiride in those with type-2 diabetes, weight gain with smoking cessation, ACE inhibitors and pneumonia risk, and the effect of speech therapy after stroke.

---

June 29th, 2012

Linagliptin and Glimepiride Compared in Type 2 Diabetes

Larry Husten, PHD

Sulfonylureas are often added to metformin to improve glycemic control, but at the known risk of increasing hypoglycemia and weight gain. In a report published in the Lancet, more than 1,500 patients with type 2 diabetes taking metformin were randomized to the addition of either linagliptin, a dipeptidyl peptidase-4 inhibitor, or glimepiride, a sulfonylurea. After two years, the trial […]

---

May 2nd, 2011

FDA Approves New Drug for Type 2 Diabetes

Larry Husten, PHD

The FDA announced today that it has approved linagliptin, a new drug for type 2 diabetes. The DPP-4 inhibitor was developed by Eli Lilly and Boehringer Ingelheim and will be sold under the brand name of Tradjenta. Linagliptin was studied in 3,800 patients with type 2 diabetes, the FDA said, and was better than placebo in […]

---